| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018，68(1): 7-30.
|
| [2] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol, 2011，22(8): 1736-1747.
|
| [3] |
Denkert C, Loibl S, Müller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial[J]. Ann Oncol, 2013，24(11): 2786-2793.
|
| [4] |
Lips EH, Mulder L, de Ronde JJ, et al. Neoadjuvant chemotherapy in ER+ HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics[J]. Breast Cancer Res Treat, 2012，131(3): 827-836.
|
| [5] |
Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol, 2018，19(1): 27-39.
|
| [6] |
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012，30(15): 1796-1804.
|
| [7] |
Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study[J]. Ann Surg Oncol, 2016，23(11): 3467-3474.
|
| [8] |
Omranipour R, Jalili R, Yazdankhahkenary A, et al. Evaluation of pathologic complete response (pCR) to neoadjuvant chemotherapy in iranian breast cancer patients with estrogen receptor positive and her2 negative and impact of predicting variables on pCR[J]. Eur J Breast Health, 2020，16(3): 213-218.
|
| [9] |
Petruolo OA, Pilewskie M, Patil S, et al. Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2017，24(9): 2556-2562.
|
| [10] |
Yang H, Zhou L, Wang S, et al. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients？[J]. Medicine (Baltimore), 2018，97(40): e12690.
|
| [11] |
Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy[J]. Eur J Cancer, 2012，48(18): 3342-3354.
|
| [12] |
Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2010，17(9): 2411-2418.
|
| [13] |
LeVasseur N, Sun J, Gondara L, et al. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis[J]. J Cancer Res Clin Oncol, 2020，146(2): 529-536.
|
| [14] |
Huang M, O’Shaughnessy J, Zhao J, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis[J]. Cancer Res, 2020，80(24): 5427-5434.
|
| [15] |
Boughey JC, Ballman KV, McCall LM, et al. Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACOSOG Z1071 (Alliance)[J]. Ann Surg, 2017，266(4): 667-676.
|
| [16] |
Sheri A, Smith IE, Johnston SR, et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy[J]. Ann Oncol, 2015，26(1): 75-80.
|
| [17] |
Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype[J]. J Clin Oncol, 2017，35(10): 1049-1060.
|
| [18] |
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007，25(28): 4414-4422.
|
| [19] |
Miglietta F, Dieci MV, Tsvetkova V, et al. Validation of residual proliferative cancer burden as a predictor of long-term outcome following neoadjuvant chemotherapy in patients with hormone receptor-positive/human epidermal growth receptor 2-negative breast cancer[J]. Oncologist, 2020，25(9): e1355-e1362.
|
| [20] |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast, 2003，12(5): 320-327.
|
| [21] |
Wang L, Luo R, Lu Q, et al. Miller-Payne grading and 70-Gene signature are associated with prognosis of hormone receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer after neoadjuvant chemotherapy[J]. Front Oncol, 2021，11: 735 670.
|
| [22] |
Brouckaert O, Paridaens R, Floris G, et al. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative[J]. Ann Oncol, 2013，24(1): 47-53.
|
| [23] |
Colleoni M, Bagnardi V, Rotmensz N, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy[J]. Breast Cancer Res Treat, 2009，116(2): 359-369.
|
| [24] |
van Mackelenbergh MT, Denkert C, Nekljudova V, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials[J]. Breast Cancer Res Treat, 2018，167(1): 59-71.
|
| [25] |
Landmann A, Farrugia DJ, Zhu L, et al. Low Estrogen Receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease？[J]. Am J Clin Pathol, 2018，150(1): 34-42.
|
| [26] |
Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update[J]. Pathology, 2017，49(2): 166-171.
|
| [27] |
Sueta A, Yamamoto Y, Hayashi M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes？[J]. Surgery, 2014，155(5): 927-935.
|
| [28] |
Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment[J]. BMC Cancer, 2011，11: 486.
|
| [29] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014，384(9938): 164-172.
|
| [30] |
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018，19(1): 40-50.
|
| [31] |
Watanabe T, Hida AI, Inoue N, et al. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers[J]. Breast Cancer Res Treat, 2018，168(1): 135-145.
|
| [32] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2006，24(23): 3726-3734.
|
| [33] |
Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study[J]. NPJ Breast Cancer, 2016，2: 16 017.
|
| [34] |
Soran A, Bhargava R, Johnson R, et al. The impact of Oncotype DX recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer[J]. Breast Dis, 2016，36(2-3): 65-71.
|
| [35] |
Pivot X, Mansi L, Chaigneau L, et al. In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy？[J]. Oncologist, 2015，20(4): 344-350.
|
| [36] |
Pease AM, Riba LA, Gruner RA, et al. Oncotype DX recurrence score as a predictor of response to neoadjuvant chemotherapy[J]. Ann Surg Oncol, 2019，26(2): 366-371.
|
| [37] |
Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, et al. Selection of neoadjuvant treatment based on the 21-gene test results in luminal breast cancer[J]. Breast, 2021，56: 35-41.
|
| [38] |
Petruolo O, Sevilimedu V, Montagna G, et al. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery？[J]. Ann Surg Oncol, 2021，28(1): 287-294.
|